COMT Inhibitor

3,5-Dinitrocatechol (Standard) (OR-486 (Standard); 3,5-Dinitropyrocatechol (Standard)) is the analytical standard of 3,5-Dinitrocatechol (HY-100959). This product is intended for research and analytical applications. 3,5-Dinitrocatechol (OR-486) is an orally active, blood-brain barrier-permeable selective catechol-O-methyltransferase (COMT) inhibitor. 3,5-Dinitrocatechol can be used in research related to Parkinson's disease, pheochromocytoma and adult cataract.

3-O-Methyltolcapone (Ro 40-7591) is a metabolite of Tolcapone (HY-17406). Tolcapone (Ro 40-7592) is a selective, potent and orally active COMT inhibitor with an IC₅₀of 773 nM. Tolcapone can inhibits α-syn and Aβ₄₂ oligomerization and fibrillogenesis. Tolcapone can cause oxidative stress and induce cancer cells apoptosis and ROS production. Tolcapone can be used for the researches of cancer and neurological disease, such as Parkinson disease and neuroblastoma.

COMT-IN-3 is a competitive inhibitor of soluble catechol-O-methyltransferase (S-COMT). COMT-IN-3 coordinates with the Mg²⁺ ion at the COMT active site via its catechol hydroxyl group, and its nitro group, as a strong electron-withdrawing substituent, further enhances the binding affinity. COMT-IN-3 interacts with the hydrophobic residues Trp38, Met40, and Trp143 at the back of the active site via its neutral nitrile tail, thereby competitively inhibiting COMT activity. COMT-IN-3 can be used in research related to Parkinson's disease.

Nebicapone (Standard) is the analytical standard of Nebicapone. This product is intended for research and analytical applications. Nebicapone (BIA 3-202), a reversible catechol-O-methyltransferase (COMT) inhibitor, is mainly metabolized by glucuronidation. Nebicapone is mainly peripherally acting inhibitor that decreases the biotransformation of L-DOPA to 3-O-methyl-DOPA by inhibition of COMT, and it is potential for the treatment of Parkinson's disease.

BIA 3-335 is an inhibitor for catechol-O-methyltransferase (COMT), and can be used in research about Parkinson's disease.

Methylspinazarin is a potent inhibitor of catechol O-methyltransferase (COMT, IC₅₀ = 0.8 μg/ml) that can be isolated from Streptomyces. Methylspinazarin is selective for COMT over tyrosine hydroxylase.